NASDAQ · Analyst Forecast

Galectin Therapeutics Inc. (GALT) Stock Forecast & Price Target

$2.91 NASDAQ: GALT Market Cap $191.64M

Price as of Nov 17, 2026 close · Analyst estimates retrieved Nov 12, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)

Revenue and earnings estimates published by analysts covering Galectin Therapeutics Inc. (GALT), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.

For Galectin Therapeutics Inc., analysts forecast revenue falling from $208.00M in 2024 to $23.10M in 2029; the average estimate for 2029 earnings per share is −$0.91; 1 analyst contribute to these figures. These are forecasts published by analysts, not results.

Analyst price targets

MeasureValue
Current priceWhat the share trades at now.$2.91
Consensus targetThe average of the price targets analysts have published.$11.00
Median targetThe middle target, less affected by a single outlier.$11.00
Highest targetThe most optimistic published target.$11.00
Lowest targetThe most pessimistic published target.$11.00
Difference from priceHow far the consensus target sits from today’s price.+278.0%

A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.

Revenue forecast (USD)

The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.

YearLowAverageHighAnalysts
2024$208.00M$208.00M$208.00M1
2025$36.32M$36.32M$36.32M1
2026$179.69M$179.69M$179.69M1
2027$385.24M$385.24M$385.24M1
2028$572.22M$572.22M$572.22M1
2029$23.10M$23.10M$23.10M1

Earnings per share forecast

YearLowAverageHighAnalysts
2024−$0.73−$0.73−$0.731
2025−$0.49−$0.49−$0.491
2026−$0.30−$0.30−$0.301
2027−$0.23−$0.23−$0.231
2028−$1.06−$1.06−$1.061
2029−$0.91−$0.91−$0.911

Galectin Therapeutics Inc. (GALT) forecast — frequently asked questions

What is the analyst price target for Galectin Therapeutics Inc.?

Analysts covering Galectin Therapeutics Inc. (GALT) have a consensus price target of $11.00, 278.0% above the current price of $2.91. Published targets range from $11.00 to $11.00. A price target is a forecast, not a measure of value, and targets are revised often.

What are analysts forecasting for Galectin Therapeutics Inc.'s earnings?

The average analyst estimate for Galectin Therapeutics Inc. (GALT) earnings per share in 2029 is -0.91, with individual estimates between -0.91 and -0.91.

How much revenue is Galectin Therapeutics Inc. expected to make?

Analysts forecast Galectin Therapeutics Inc. (GALT) revenue of $23.10M in 2029, based on 1 published estimates.

How many analysts cover GALT?

1 analyst contribute estimates for Galectin Therapeutics Inc. (GALT). Thin coverage makes an average less reliable.

Analyst forecasts for other Biotechnology stocks

VRTX forecastREGN forecastMRNA forecastRVMD forecastROIV forecastINSM forecastUTHR forecastINCY forecastALNY forecastASND forecastAll Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.